Life Sciences

  • February 06, 2026

    TPG Hid Exactech Defects To Dodge Liability, Trust Alleges

    The settlement trust of joint implant maker Exactech filed a billion-dollar lawsuit in Delaware Chancery Court against TPG Inc., accusing the private equity firm of controlling Exactech after buying it in 2018, concealing the implants' defects, delaying product recalls and pushing the company into Chapter 11 to avoid liability.

  • February 06, 2026

    SEC Alleges Pharma Co. Misled Investors About Cancer Drug

    The U.S. Securities and Exchange Commission is suing a Kentucky pharmaceutical company for securities fraud based on claims that the company raised $4.1 million by lying to investors about the status of its cancer treatment drug.

  • February 06, 2026

    Beasley Allen Disqualified From NJ Talc Multicounty Litigation

    A New Jersey state appeals court disqualified the Beasley Allen Law Firm from representing plaintiffs in multicounty litigation over Johnson & Johnson's talc-based baby powder, ruling Friday that a former Faegre Drinker Biddle & Reath LLP lawyer's collaborative efforts with the firm's attorneys violated ethics rules.

  • February 06, 2026

    Insulet Gets $14.9M Fee Award For Trade Secret Trial Win

    A Massachusetts federal judge awarded Insulet Corp.'s attorneys almost $15 million for their $452 million jury trial victory in a trade secrets dispute that was later reduced to $59.4 million, but the fees Goodwin Procter LLP netted were significantly less than the nearly $25 million it requested.

  • February 06, 2026

    FLSA Does Not Bar Claim Waivers, Wash. Judge Says

    The Fair Labor Standards Act does not categorically bar a contract's release of an employee's claims, a Washington federal judge ruled, finding that a former pharmaceutical manufacturing company worker's severance agreement that included a general release of claims precludes his wage suit.

  • February 06, 2026

    HHS Ends 340B Drug Rebate Pilot After Legal Challenge

    The U.S. Department of Health and Human Services has ended a proposed rebate program that would have altered how hospitals receive payments for participating in the federal 340B drug discount program, which provides discounted prescription drugs for low-income Americans, after facing a lawsuit from a major hospital association.

  • February 05, 2026

    NYAG's Insider Trading Case A Power Grab, Judge Told

    The former CEO of healthcare contractor Emergent BioSolutions Inc. has removed to federal court New York Attorney General Letitia James' insider trading case against him, alleging James is trying to expand her office's power through claims that concern questions of federal law.

  • February 05, 2026

    Full Fed. Circ. Won't Rethink Heart Monitor Patent Claim Ax

    The full Federal Circuit won't rethink a panel's refusal to revive claims in a wireless heart rate monitor patent owned by Finnish sports tech company Polar Electro Oy that a lower court found were invalid.

  • February 05, 2026

    Judge Affirms Health Cos.' Sanctions For Witness Omission

    An Illinois federal judge rejected a "vague and unsupported" bid by a home healthcare company accused of violating federal kickback laws to reconsider sanctions she ordered for failing to disclose witnesses, saying the motion "wastes everyone's time" and scolding the defendants for "impugning the character and professionalism of an able magistrate judge."

  • February 05, 2026

    David Protein Gets Ingredient Supply Antitrust Claims Tossed

    A New York federal court dismissed a lawsuit from several low-calorie food producers accusing protein bar-maker David Protein of refusing to sell them a fat replacement ingredient after it purchased the ingredient's only supplier.

  • February 05, 2026

    Patent Co., AI Research Firm Join Forces In $150M Deal

    Patent monetization venture SIM IP has announced a merger valued at $150 million with artificial intelligence research firm Garden Intel, a deal the companies said would create a first-of-its-kind platform.

  • February 05, 2026

    Novo Threatens Hims & Hers With Suit Over GLP-1 'Knockoff'

    Novo Nordisk said in a Thursday announcement it plans to take legal action against Hims & Hers Health Inc. after the telehealth company revealed a "knockoff" version of Novo's popular weight loss drug Wegovy earlier in the day. 

  • February 05, 2026

    Medtronic Hit With $382M Antitrust Verdict Over Bundling

    A California federal jury on Thursday ordered Medtronic to pay nearly $382 million to business rival Applied Medical for antitrust violations, finding the medical device giant illegally used its monopoly power to crush competition in the market for a type of surgical instrument called an advanced bipolar device.

  • February 05, 2026

    Yale Health System Seeks $4.1M Coverage For Transplant

    A Liberty Mutual unit breached a stop-loss insurance policy by denying Yale University's health system $4.1 million in coverage for a plan member's bone marrow transplant, the system told a Connecticut federal court.

  • February 05, 2026

    Trump Admin Finalizes Rule Facilitating Federal Worker Firings

    The Trump administration Thursday announced a final rule to create a new category of federal workers who would have fewer job protections and be easier to fire, implementing an executive order from early last year that could affect 50,000 employees at federal agencies.

  • February 05, 2026

    Covington, Davis Polk Lead Eikon's Upsized $381M IPO

    Oncology-focused biopharmaceutical company Eikon Therapeutics began trading publicly Thursday after raising $381 million in its upsized initial public offering.

  • February 04, 2026

    Ropes Leads Hair-Loss Firm Veradermics' Upsized $256M IPO

    Hair loss drug developer Veradermics Inc. began trading Wednesday after raising $256 million in an upsized initial public offering, with Ropes & Gray LLP representing the company and Cooley LLP representing the underwriters.

  • February 04, 2026

    'Careless Or Disingenuous': Judge Rips CareFirst Rethink Bid

    A Virginia federal judge Wednesday refused to reconsider an order reversing course and throwing out key claims in CareFirst's suit against Johnson & Johnson over the immunosuppressive drug Stelara, calling CareFirst's arguments for doing so "either careless or disingenuous."

  • February 04, 2026

    Medtronic Owes $381M For Antitrust 'War Games,' Jury Told

    An attorney for Applied Medical told a California federal jury Wednesday during closing arguments in an antitrust trial against Medtronic that internal documents from the medical device giant show it played illegal "war games" against his client and should pay up to $381 million. 

  • February 04, 2026

    Fed. Circ. Leans Toward Vacating $12.7M Copyright Award

    The Federal Circuit appeared likely to vacate a $12.7 million copyright infringement award against the federal government on Wednesday, pressing attorneys for a software developer and the government to answer what instructions should be given to the claims court on remand.

  • February 04, 2026

    Class Attys In Del. Northwest Biotherapeutics Praise Deal

    Delaware Chancery Court has lined up a March 16 settlement hearing for a four-year stockholder lawsuit alleging insiders of Northwest Biotherapeutics Inc. received $40 million in stock awards, with proposals including a call for the company to forfeit nearly 22.9 million stock options and it receiving $2.25 million.

  • February 04, 2026

    Teva Wins 1st Paragard IUD Bellwether Trial

    Teva Pharmaceuticals won a complete defense verdict Tuesday in the first trial testing claims that the company failed to warn consumers that its Paragard IUD has a defect making it prone to breakage inside patients' uteri.

  • February 04, 2026

    Walgreens Says Audio Recording Refutes Shareholders' Claim

    Walgreens told an Illinois federal judge Tuesday that newly discovered evidence warrants revisiting a decision allowing shareholders' claim over an executive's allegedly false statement to move forward, saying an audio recording shows "no basis to conclude the actual statement was false or misleading when made."

  • February 04, 2026

    Teva Fights Class Cert. Bid In Effexor Antitrust Case

    Teva Pharmaceuticals urged a New Jersey federal judge Wednesday to reject a class certification bid by a group of direct buyers of the antidepressant drug Effexor XR and its generic versions, arguing that the proposed class failed to carry its burden showing that joinder is impracticable.

  • February 04, 2026

    Stem-Cell Drug Developer PrimeGen Inks $1.5B SPAC Merger

    Regenerative medicine developer PrimeGen US said Wednesday it has agreed to go public through a merger with blank check company DT Cloud Star Acquisition Corp., in a deal that values the company at about $1.5 billion.

Expert Analysis

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Software Patents May Face New Eligibility Scrutiny

    Author Photo

    November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

  • Riding The Changing Winds For AI Innovations At The USPTO

    Author Photo

    As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.

  • Series

    The Law Firm Merger Diaries: Integrating Practice Groups

    Author Photo

    Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.

  • Opinion

    Supreme Court Term Limits Would Carry Hidden Risk

    Author Photo

    While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Next Steps For Orgs. Amid Updated OpenAI Usage Policies

    Author Photo

    OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.